Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biopharmaceutical pioneer leveraging computational discovery to advance novel cancer immunotherapies. This news hub provides investors and researchers with timely updates on clinical trials, strategic partnerships, and therapeutic innovations emerging from Compugen's AI-driven platform.
Access authoritative updates on key developments including COM701 (anti-PVRIG), COM902 (anti-TIGIT), and collaborative programs with industry leaders. Our curated news collection simplifies tracking of pipeline progress, peer-reviewed research publications, and milestone achievements in immuno-oncology.
Content spans clinical trial results, regulatory milestones, and partner collaboration updates, offering a comprehensive view of Compugen's position in next-generation cancer treatment development. Bookmark this page for streamlined access to verified information about therapeutic candidates and computational discovery breakthroughs.
Compugen (NASDAQ: CGEN) has announced the dosing of its first patient in a Phase 1 clinical trial for COM503, a potential first-in-class antibody against IL-18 binding protein licensed to Gilead Sciences. The multi-center trial will evaluate COM503's safety, tolerability, and pharmacokinetics both as a monotherapy and in combination with Gilead's anti-PD1, zimberelimab, in patients with advanced solid tumors.
The trial, initiated in Q4 2024, represents a new approach to cancer treatment through cytokine biology. Compugen's Unigen™ discovery engine identified high IL-18 expression in cancer patients' tumors, but found its anti-tumor activity is blocked by an endogenous IL-18-binding protein. COM503 works by blocking this protein, potentially enabling naturally occurring IL-18 to fight cancer within tumors, addressing limitations of systemic cytokine administration.
The first patient was dosed at the START Center for Cancer Research-Midwest in Grand Rapids, Michigan, with Compugen responsible for conducting the Phase 1 trial.
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment. The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduced Fc clinical-stage antibody, in combination with any anti-PD-1 and anti-PVRIG antibodies. The patent is set to expire no earlier than August 2037.
The company highlights that recent developments suggest potential advantages of anti-TIGITs without active Fc binder, like COM902. Their data indicates blocking TIGIT alone may be insufficient for optimal anti-tumor activity in certain cases, particularly in tumors non-responsive to PD-1 inhibition.
Compugen (NASDAQ: CGEN) reported Q3 2024 financial results and corporate updates. The company presented clinical data for COM701 at SITC 2024, showing durable responses in immunotherapy-resistant tumors. Plans include initiating an adaptive platform trial for COM701 in Q2 2025 for ovarian cancer patients. The company reported $17.1 million in revenues and a net profit of $1.3 million for Q3 2024. Cash position stands at $113.2 million, expected to fund operations into 2027. Partner AstraZeneca advanced rilvegostomig into additional Phase 3 trials, while COM503's Phase 1 trial is set to begin in Q4 2024.
Compugen (Nasdaq: CGEN) announced its participation in the Stifel 2024 Healthcare Conference in New York City. The company's management will engage in a fireside chat scheduled for Monday, November 18, 2024, at 8:35 am ET. The event will be accessible through a live webcast on the Investor Relations section of Compugen's website, with a replay available after the event. Compugen, operating as a clinical-stage cancer immunotherapy company, is known for its pioneering work in computational target discovery.
Compugen (CGEN) has announced promising data on the triple combination of COM701, COM902, and pembrolizumab in treating platinum-resistant ovarian cancer patients. The data will be presented at the SITC 2024 conference in Houston, Texas. The study showed a 17.4% confirmed objective response rate and a 43.5% disease control rate in 23 evaluable patients.
The treatment demonstrated a favorable safety profile with mostly Grade 2 or lower adverse events, and only one Grade 3 event reported. Dr. Oladapo Yeku from Harvard Medical School highlighted the treatment's durability and effectiveness in late-stage ovarian cancer patients. The company plans to advance COM701 to earlier stages of ovarian cancer therapy, particularly targeting patients who are ineligible for maintenance treatment.
Daiichi Sankyo and AstraZeneca have initiated three global Phase 3 trials evaluating datopotamab deruxtecan (Dato-DXd) combinations in advanced nonsquamous non-small cell lung cancer (NSCLC). The trials include: TROPION-Lung10 testing Dato-DXd plus rilvegostomig in high PD-L1 expression patients; TROPION-Lung14 evaluating Dato-DXd plus osimertinib in EGFR mutated NSCLC; and TROPION-Lung15 studying Dato-DXd with/without osimertinib in EGFR mutated NSCLC that progressed on osimertinib. These trials are part of the expanding TROPION program, which now includes seven Phase 3 trials.
Compugen (Nasdaq: CGEN) announced it will release its Q3 2024 financial results on Tuesday, November 12, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET to discuss financial results and provide a corporate update. Management will also discuss data presented at the Society for Immunotherapy of Cancer Annual Meeting (November 8-10, 2024). The conference call will be accessible via phone and live webcast through Compugen's website, with a replay available afterward.
Compugen (Nasdaq: CGEN) has announced that new clinical data will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 8-10, 2024. The presentation will focus on the anti-tumor activity and safety of a triple combination therapy involving COM701, COM902, and pembrolizumab in heavily pre-treated patients with platinum-resistant ovarian cancer.
The poster presentation, titled "Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows preliminary antitumor activity in patients with platinum resistant ovarian cancer, interim results of Phase I trial," will be delivered by Dr. Oladapo Yeku, a Medical Oncologist from Massachusetts General Hospital, on Friday, November 8, 2024. The abstract number for this presentation is 985.
Compugen (Nasdaq: CGEN) will present at the Single Cell Genomics 2024 conference in Greece from September 16-18, 2024. Dr. Roy Granit, Head of Computational Discovery, will showcase a poster on applying AI to gain insights into the novel immune checkpoint PVRIG through single-cell and spatial transcriptomics.
The presentation highlights additional biological insights generated using Compugen's AI/ML-powered computational discovery platform, UnigenTM. These findings support the potential of PVRIG inhibition to induce anti-tumor activity in indications previously resistant to immunotherapy, differentiating it from other immune checkpoints.
The poster presentation, titled 'Applying AI to Gain Insights into the Novel Immune Checkpoint PVRIG Through Single-Cell and Spatial Transcriptomics,' is scheduled for Monday, September 16, 2024. It will be available on Compugen's website following the presentation.
Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for 30 days on the company's Investor Relations website.
Compugen, known for its pioneering work in computational target discovery, aims to showcase its latest developments and strategies to investors and industry professionals. This presentation offers an opportunity for stakeholders to gain insights into Compugen's progress in the competitive field of cancer immunotherapy.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
